NCT00222729View on ClinicalTrials.gov

Study of Pemetrexed and Bevacizumab in Patients With Head and Neck Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

November 30, 2005

Primary Completion Date

October 31, 2013

Study Completion Date

October 31, 2013

Conditions
Cancer
Interventions
DRUG

Pemetrexed

500 mg/m2 day 1 q 21 days

DRUG

Bevacizumab

15 mg/kg IV q 21 days following pemetrexed

Trial Locations (1)

15216

Hillman Cancer Center, Pittsburgh

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

collaborator

Genentech, Inc.

INDUSTRY

lead

University of Pittsburgh

OTHER

NCT00222729 - Study of Pemetrexed and Bevacizumab in Patients With Head and Neck Cancer | Biotech Hunter | Biotech Hunter